Introduction
============

Alzheimer's disease (AD) is a chronic neurodegenerative disease which was first described by Alois Alzheimer ([@B37]). The disease usually has concealed onset and gets progressively worse. It is characterized by irreversible loss of memory and cognitive decline. It is generally considered the most common dementia subtype. To date, it is estimated that approximately 42 million people now have dementia globally. Aging is a crucial risk factor for AD, with the aging of the population becoming increasingly more common, AD is becoming one of the most serious threats to public health. So far, the cause of the disease is still debated, and environmental and genetic factors seem to be critical influences on AD.

In recent years, the relationship between diet patterns and AD has drawn the attention of researchers. According to the worldwide epidemiological investigation of Alzheimer's disease, the Europeans and Americans are believed to have higher prevalence and incidence rates of AD. According to worldwide diet pattern research, there are some differences between the Eastern and Western diets. Westernized diets tend to include meat, sweets, and high-fat dairy products, which are found to be risk factors for AD ([@B36]); for instance, when Japan made a nutritional transition from the traditional Japanese diet to a Western-pattern diet, AD rates rose from 1% in 1985 to 7% in 2008 ([@B26]). That is, the Western diet may be a risk factor for Alzheimer's disease.

Additionally, diet is one of the factors that influence constipation. Through global epidemiological investigations, we found that, compared with North America, Europe and Oceania, Asian countries seem to have lower constipation morbidity rates ([@B68]).

In addition, when Japanese people transformed their diet pattern from a traditional diet to a Western diet, not only did AD incidence increase dramatically but also their risk of colon cancer was much higher ([@B107]).

Colorectal cancer, with higher incidence in Western countries and lower incidence in Eastern countries, has been found in many studies to be related to high meat consumption and low vegetable intake, which is the major food pattern of Westernized diets. This pattern is one of the main causes leading to high colorectal cancer incidence ([@B11]), and a correlation between constipation and colorectal cancer has been found in the majority of studies.

Therefore, in this essay, we aim to present the possible epidemiological resemblance between constipation and Alzheimer disease, and put forward the hypothesis that diet and constipation might impact the progression of Alzheimer's disease in a similar way that they influence colorectal cancer.

The Association Between Epidemiological Investigation of Alzheimer's Disease, Colorectal Cancer and Constipation
================================================================================================================

Epidemiological Investigation of AD
-----------------------------------

In 2015, there were approximately 29.8 million people worldwide suffering with Alzheimer's disease. Alzheimer's disease is well-known as the main cause of dementia and generally considered to produce low later life quality ([@B114]). Alzheimer's disease is characterized by memory loss, extracellular amyloid plaque deposition involving the Aβ peptide and intracellular tangles of tau protein accompanied with reactive microgliosis, dystrophic neurites, and loss of neurons and synapses ([@B53]), and alteration in the production and processing of amyloid β-protein has been hypothesized as the major initiating factor. However, the underlying causes of these pathological changes remain unclear, but increasing age and genetic and non-genetic factors may be essential influences ([@B92]).

The prevalence of AD has been found to be associated with increasing age; for instance, as age increases from 65--74 years to 85 years or older, the prevalence of AD, correspondingly, rises from 3 to 50% ([@B16]). With the worldwide incidence rate of AD increasing rapidly, AD is becoming one of the most serious threats to public health. In the United States, the prevalence of AD is estimated to experience double-digit to triple-digit percentage increases between 2010 and 2025 ([@B119]).

According to several worldwide epidemiological investigations of Alzheimer's disease, we found that Europeans and Americans are believed to have higher prevalence and incidence rates of AD. Some researchers identified 27 studies reporting age-specific incidence rates for AD, from which they found that the incidence of AD at age 80 in Europe and North America was higher than that in other countries ([@B122]). [@B58] compared the incidence data from eight population-based studies in Europe, which suggested that prevalence of AD in those \>65 years of age was 4.4%, which was higher than that of Nigeria (1.4%) and India (1.1%) ([@B58]). Moreover, a meta-analysis of the prevalence and incidence of dementia due to Alzheimer's disease provided more specific data; within the community settings (30.4 per 1000 persons), the estimated annual period prevalence for North America was 103.6 per 1000 persons, which was much higher than the annual period prevalence of Asia (11.7 per 1000 persons) and that in Europe (31.3 per 1000 persons) ([@B32]).

In 2005, Alzheimer's Disease International managed an evidence-based Delphi consensus on dementia prevalence worldwide, and the Delphi study showed that in 2001, an estimated 24 million people had dementia ([@B30]); the majority of these people are thought to have had Alzheimer's disease. There is one research study that provided dementia data on people aged above 60 years in different places, and the data indicated that the prevalence in North America was 6.3%, Western Europe was 5.3%, Latin American was 4.9%, China was 4.0%, and the Western Pacific area was 4.0% ([@B30]); people from North America and Western Europe had the highest incidence, and China and the Western Pacific area had the lowest incidence. Moreover, similar conclusions were drawn in several passages in a 2012 Alzheimer's disease epidemiology paper in which the author found that dementia prevalence using DSM-IV criteria was extremely low in low-income places, and the author declared that dementia prevalence was estimated to be 4.7% worldwide, with Americans at 6.5%, Europeans at 6.2%, and Asians at 3.9% ([@B97]).

In particular, Japan is a Westernized Asian country, and compared to other Asian countries, Japan has relatively higher prevalence/incidence of some diseases. One study described the trends in Alzheimer's disease prevalence in Japan as 1.5% in 1985, 1.4% in 1992, 2.4% in 1998, 3.9% in 2005, and 7.2% in 2012 (*p* for trend \<0.01); the increasing trend is apparent, and we chose the most recent AD prevalence data from Japan for the figure for better comparison ([@B72]).

Based on the data we collected from diverse research, we present our information in **Table [1](#T1){ref-type="table"}**.

###### 

Characteristics of included studies.

  Region            Country          Study           Time         Dementia prevalence
  ----------------- ---------------- --------------- ------------ ---------------------
  North America                      [@B80]          2009         6.46
                    United States    [@B88]          2001         7.5
  Latin America                      [@B65]          2012         4.9
                    Brazil           \(1\) [@B91]    2002--2008   5.3
                                     \(2\) [@B19]                 
                                     \(3\) [@B10]                 
                                     \(4\) [@B43].                
                    Argentina        [@B73]          1999         11.5
                    Colombia         \(1\) [@B89]    2000         2.1
                                     \(2\) [@B78]                 
  Europe                             [@B97]          2012         6.2
  Western Europe                     [@B65]          2012         5.3
                    Greece           [@B110]         1993         9.59
                    Spain            [@B58]          1990--2008   9.8
                    France           [@B71]          1997         9.2
                    Sweden           [@B82]          1990--2000   17.7
                    Norway           [@B29]          1880--1920   16.3
                    England          [@B63]          2011         8.3
                    Finland          [@B103]         1985         9.2
                    Italy            [@B87]          1990         6.2
                    Holland          [@B13]          1992         8.5
  Asia                               [@B97]          2012         3.9
  Southeast Asia                     [@B80]          2009         6.38
  Western Pacific                    [@B65]          2012         4.0
                    India            [@B97]          2012         1.1 (AD)
                    South Korea      [@B49]          2008         9.2
                    Japan            [@B72]          2012         7.2
                    Taiwan, China    \(1\) [@B58]    1995--1998   3.2
                                     \(2\) [@B56]                 
                                     \(3\) [@B57]                 
                    China mainland   [@B27]          1980--2004   3.1
                    Turkey           [@B2]           2009         8.4
  Other countries                                                 
                    Nigeria          [@B97]          2012         1.4 (AD)
                    Australia        [@B80]          2009         6.91
                                                                  

From these studies, we can infer that the prevalence of dementia and Alzheimer's disease was lower in developing or low and middle income countries \[11, 12, 16, 17\]; the difference between the developed and developing countries was very large in some studies ([@B42]; [@B20]). However, there were a number of statistics about the studies on Alzheimer's disease and dementia prevalence; Western Europe had 61 studies, and East Asia had 34 studies. The high income area of Pacific Asia had 22 studies, North America had 13 studies, Latin America had 11 studies, South Asia had 7 studies, South East Asia had 5 studies, Australasia had 4 studies, and there were also some places with just a few studies. The Caribbean had 4 studies, Central Europe had 4 studies, North Africa/Middle East had 2 studies, Eastern European had 1 study, and Southern sub-Saharan Africa had 1 study; even though we have known that since the mid-1990s the number of studies in low income countries has increased dramatically, it is clear that there are still more studies in developed countries, and to assume that developing countries have lower incidence, we need more valid studies in those countries.

Epidemiological Investigation of Colorectal Cancer
--------------------------------------------------

Colorectal cancer is one of the most common cancers in Western countries, and its incidence/prevalence has tended to increase worldwide. At the end of the 20th century, approximately one million colorectal cancer cases came up worldwide every year, almost equal to one tenth of all new cases of cancer ([@B99]).

In the United States, colorectal cancer is the third most common cancer and the second most common cause of cancer death. Among all these countries worldwide, India has the lowest rates, and Japan has the highest rates. Moreover, researchers found that colorectal cancer incidence rates increase acutely with age, and colon cancer occurs equally in both sexes, whereas rectal cancer occurs twice as frequently in men as in women ([@B77]). Colorectal cancer incidence rates vary dramatically all over the world, and as of 2012, it was the second most common cancer in women (9.2%) and the third most common cause of cancer in men (10.0%); it was the fourth most common cause of cancer death. In 2014, there were 71830 men and 65000 women estimated to be diagnosed with this disease, and more than a third of them will die from this disease ([@B94]).

Western societies are thought to have higher colorectal cancer incidence rates ([@B12]). However, studies from the Cancer Base of the International Agency for Research on Cancer (IARC) showed that the incidence rate in some developed and Westernized Asian countries, especially Japan, are now increasing to almost the same level as the West ([@B105]).

Based on the studies, we found that, generally, worldwide colorectal cancer prevalence is higher in Western countries and lower in Eastern countries. The collection of colorectal cancer epidemiology data is shown in **Figure [1](#F1){ref-type="fig"}** ([@B105]; [@B18]).

![Comparison of different countries' colorectal cancer incidence (age standardized incidence per 100000). As the epidemiological data on colorectal cancer were collected from diverse studies \[including Cancer incidence in five continents ([@B22])\], their criteria and dates are apparently different; for better comparison, we evaluated and compared the data in each study and divided the data into three groups (relatively high, relatively medium, and relatively low group) artificially.](fnagi-10-00176-g001){#F1}

According to the research of international variation and immigration data, colorectal cancer has been shown to be highly sensitive to environmental factors. One passage gave the example that immigrants and their offspring reach the local cancer morbidity number in a short time ([@B77]). Diet and other local cultural factors are possibly major causes. Moreover, the majority of the case-control studies showed that meals with more vegetables and fruit are correlated with lower risk of colorectal cancer ([@B77]). Many studies have shown that Eastern countries tend to have lower incidence of colorectal cancer than Western countries. According to studies about colorectal cancer epidemiology, diets high in fat, meat, animal protein and low in fiber, vegetables and fruits is an important risk factor ([@B11]), which is also a risk factor for Alzheimer's disease.

Epidemiological Investigation of Constipation
---------------------------------------------

Constipation is a very common gastrointestinal disease affecting all age group, and people tend to define it as bowel symptoms (difficult or infrequent passage of stool, stool hardness, or a feeling of unfinished evacuation). Based on the definition, with either self-reported or Rome criteria, constipation occurs in 2--20% of the population ([@B59]). It troubles patients physically and mentally and dramatically affects people's daily life and well-being; additionally, the health costs of constipation are tremendous; in the United States, constipation-relevant health treatment costs 6.9 billion dollars every year, and constipation is reported to occur more frequently in the elderly; as life expectancy is increasing, an elevation in the prevalence of constipation is promised to come, alongside negative effects on life quality and the burden to society and the economy.

For a disease people are familiar with, constipation has actually quite high incidence in human kind, and to further study it, research from diverse countries have collected data. [@B81] used a cluster random sampling method to investigate the elderly (≥60 years) in six cities (Beijing, Shanghai, Guangzhou, Xian, Shenyang, Chengdu) in China; they found that the crude prevalence rate of constipation is 11.5% ([@B81]); a constipation epidemiology study in the United States showed that the overall prevalence of constipation was 14.7% ([@B100]); one study showed the pooled prevalence of chronic idiopathic constipation in diverse countries as follows: South East Asia was 11%, North America was 14%, Northern Europe was 16%, Southern Europe was 16%, and South America was 18% ([@B102]). One research study revealed that the prevalence of constipation in the general population (in Germany) was 14.5%, which was much higher than their previously reported prevalence and similar to data in other European countries ([@B28]). A survey according to Rome I criteria described the constipation prevalence in Canada to be 16.7% ([@B76]).

One study described that the Japanese prevalence of constipation in men was 11.9%, and it was 31.8% in women; overall, it was 23.0% ([@B117]).

The information of individual studies is shown in **Table [2](#T2){ref-type="table"}**.

###### 

Characteristics of included studies.

  Region            Country          Study                Time                      Constipation prevalence
  ----------------- ---------------- -------------------- ------------------------- -------------------------
  North America                      [@B102]              2011                      14
                    United States    [@B100]              1999                      14.7
                    Canada           [@B76]               2011                      16.7
  South America                      [@B102]              2011                      18
                    Brazil           [@B116]              2010                      16.7
                    Argentina        [@B115]              2010                      14.2
                    Colombia         [@B115]; countries   2010                      21.7
  Northern Europe                    [@B102]              2011                      16
  Southern Europe                    [@B102]              2011                      16
                    Germany          [@B28]               2015                      14.5
                    Greece           [@B75]               2006                      14
                    France           [@B95]               2003                      22.4
                    Sweden           [@B66]               2001                      31.4
                    Norway           [@B40]               2002                      20.2
                    England          [@B106]              1980                      20.6
                    Finland          [@B52]               1991                      29
                    Italy            [@B34]               1989                      9.2
                    Holland          [@B111]              Late 1980s- Early 1990s   14.2
                    Spain            [@B35]               2004                      29.5
  South East Asia                    [@B102]              2010                      11
                    Taiwan, China    [@B60]               2001                      8.5
                    China mainland   [@B81]               2001                      11.3
  Other countries                                                                   
                    South Korea      [@B55]               2000                      24.3
                    Japan            [@B117]              1990                      23
                    Australia        [@B21]               2000                      27.7
                    Turkey           [@B74]               2003                      29.8
                                                                                    

The Possible Relationship Between AD and Constipation
-----------------------------------------------------

Eastern countries appear to have lower constipation and dementia prevalence through observing the Alzheimer's disease and constipation prevalence data in **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**. Based on the similarity of the prevalence distributions of these two diseases, we speculate that Alzheimer's disease may correlated with constipation, which means either they may share a common factor, or one disease could contribute to the occurrence of the other disease.

To demonstrate the relation between constipation and AD, data in **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}** which did not meet criteria, including comparable study year and area, were excluded. Statistical analysis was used to analyze the correlation between AD and constipation. Dementia prevalence was used to do the correlation analysis as AD makes up almost 70% of dementia ([@B14]).

The correlation analysis revealed a positive correlation between Dementia prevalence and constipation prevalence (**Figure [2](#F2){ref-type="fig"}**). Hence, the location with higher constipation prevalence inclined to have higher Alzheimer's disease prevalence, which may further prove the hypothesis that these two disease are related or one disease is involved in the pathogenesis of the other disease.

![The correlation analysis result between Constipation and Dementia prevalence. This figure is the result of correlation analysis between constipation prevalence and Dementia prevalence. Constipation prevalence is the *Y*-axis, and Dementia prevalence is the *X*-axis. *R* = 0.468 means the correlation coefficient of this analysis is 0.468, and alongside with *P* = 0.0325 \< 0.05 indicate constipation prevalence is positive correlated with Dementia prevalence.](fnagi-10-00176-g002){#F2}

A Possible Mechanism Underlying the Association Between Constipation and AD
===========================================================================

Gut-Brain Axis and Gut Microbiota
---------------------------------

The gut and the brain are connected through the gut-brain axis ([@B86]). The CNS communicates with the gut nervous system, enteric mucosa and muscle layer via bidirectional (i.e., afferent and efferent) paths and can control enteric movement, immune reaction and mucus secretion. The central nervous system, autonomic nervous system, brain and spinal cord, enteric nervous system, and the hypothalamic pituitary adrenal are part of this bidirectional pathway ([@B15]).

The gut-brain axis can connect brain emotional and cognitive centers with intestinal function, and also, as one significant part of the intestinal environment, gut microbiota have been shown to be important in the gut and brain interaction. It was suggested by clinical data and studies that gut microbiota could locally influence the intestinal cells and enteric system. Moreover, gut microbiota can directly interact with the central nervous system by neuroendocrine and metabolic paths([@B15]). The role of microbiota in the gut-brain axis was first discovered more than 20 years ago when patients with hepatic encephalopathy improved their condition dramatically with administration of oral antibiotics ([@B67]). Meanwhile, increasing studies showed that the gut microbiota are one essential part influencing anxiety and depression ([@B33]; [@B70]). Moreover, the association between gut bacteria alteration and the severity of symptoms has been observed in autism patients ([@B96]; [@B64]).

Gut-brain axis disruption could cause gastrointestinal motility and secretion alteration and lead to visceral hypersensitivity, giving rise to cellular transformation of the immune system and gastrointestinal endocrine system. Gut microbiota may play an essential role in those diverse pathophysiological mechanisms. Crouzet L and colleagues showed that visceral sensitivity, which is characterized by irritable bowel disease, could be shifted to germ-free rats by using the gut bacteria of irritable bowel disease patients.

Research on germ-free animals has revealed that the gut microbiota is essential in central nervous system and enteric nervous system development and maturation ([@B6]; [@B101]).

Evidence shows that the gut microbiota interacts with the brain through the vagus nerve, which could connect the luminal environment with the central nervous system. Gut microbiota may also interact with the gut-brain axis by affecting the sensory nerves. There have been reports that *Lactobacillus reuteri* could increase the excitability of the nerves by suppressing the calcium-dependent potassium channels; thus, gut microbiota would be able to influence gut motility and pain perception ([@B54]). By generating substances that can function local transmitters, such as GABA, serotonin, histamine, melatonin, and acetylcholine ([@B46]), and creating active state catecholamines in the gastrointestinal lumen, gut microbiota can affect enteric nervous system excitability ([@B3]). Moreover, gut microbiota have shown the ability to activate the gastrointestinal mucosal immune system ([@B113]).

One principle product of gastrointestinal bacteria is short-chain fatty acids, which include butyric acid, propionic acid, and acetic acid, and the enteric nervous system can be affected by these substances; these metabolites can also influence the sympathetic system ([@B51]), increase mucosal serotonin release and affect learning and memory function ([@B112]; [@B98]).

On the other hand, the brain can also affect the gut microbiota. It has also been shown that under the influence of short stressors, the gastrointestinal microbiota can change dramatically. After only a 2-h social stressor, the bacteria community alteration and the reduction of main microbiota phyla is evident. In addition, the brain can influence gastrointestinal bacteria function and composition by modulating intestinal permeability, which leads to the penetration of gastrointestinal bacteria through the gut epithelium, thus producing an immune reaction in the gastrointestinal mucosa ([@B90]). Input from the gastrointestinal system to the CNS can also contribute to several symptoms, and the CNS and gastrointestinal system are linked via the gut-brain axis.

Constipation and Gastrointestinal Condition Alteration
------------------------------------------------------

Constipation is a worldwide disease that affects almost one-third of the general population during their lifetime; its chronic symptoms seriously impair patient life quality and produce heavy economic burden for patients and society ([@B104]; [@B38]).

The gut microbiota have an important role in maintaining gastrointestinal environment stability. It is reported that gut microbiota are correlated with gastrointestinal motility ([@B6]), and another group demonstrated that intestinal bacteria could influence the migrating myoelectric complex, which are waves of electrical activity that sweep through the intestine in a regular cycle during fasting in a germ-free rat model ([@B45]). Some studies showed that gut microbiota could affect gut immune response system to release mediators, which are bacterial fermentation end-products and intestinal neuroendocrine factors, to influence gastrointestinal motor ability ([@B6]; [@B83]; [@B120]). Additionally, gastrointestinal microflora play an essential role in the human body to provide nutrition, which regulates the gastrointestinal epithelium and modulates innate immunity.

The cause of constipation is still unclear, and the alteration of gut microbiota has been shown to be one possible pathophysiologic mechanism ([@B5]; [@B8]; [@B84]). An experiment using humanized (ex-germ-free mice transplanted with human fecal microflora) mice described that the change in gastrointestinal motility could lead to the alteration of gut microbiota; furthermore, with the administration of polyethylene glycol or a non-fermentable cellulose-based diet, which affects gastrointestinal motility, the mice exhibited similar alteration of gut microbiota ([@B47]). Regardless of whether the gut microbiota composition variation is a cause or a consequence of constipation, the correlation between gut microbiota alteration and constipation was shown in this experiment.

Another study [@B48] demonstrated that relief of constipation tends to normalize the gut microbiota and concluded that gastrointestinal flora alteration is more likely to be the result of constipation rather than the cause of it.

By far, the abundance or lack of certain kinds of bacteria due to constipation is poorly characterized, and there are contradicting data. [@B50] used quantitative real-time polymerase chain reaction to investigate the gut microbiota traits in patients with functional constipation. They found that *Bifidobacterium* and *Bacteroides* species had lower abundance in feces from the functionally constipated patients compared with the control group, and no significant differences were found in the proportion of *Lactobacillus*, *Escherichia coli* and *Clostridium species*. Another study found that *Bifidobacterium* and *Lactobacillus* were less abundant in adult patients with constipation ([@B48]). However, a study of children with constipation revealed that the abundance of *Bifidobacteria* and *Clostridia* were increased in their feces compared with the control group ([@B124]). Another study found significantly decreased levels of *Prevotella* in patients with constipation by using 16S rRNA gene pyrosequencing ([@B121]).

Gut Microbiota Alteration and AD
--------------------------------

The intestinal bacteria are defined as an aggregation of gut living microorganisms, and their concentration is approximately 10^11^--10^12^cells/g in the gastrointestinal cavity. The amount of gastrointestinal bacteria is almost 10 times than that of human body cells.

Gut microbiota play an important role in maintaining a normal gut environment and modulating the signal along the gut-brain axis. Gut microbiota alteration and the increase in intestinal permeability may cause an overall systemic inflammation, neuroinflammation and dysfunction of particular brain regions, such as the cerebellum and hippocampus ([@B23],[@B24]), and may also cause insulin resistance, which has been shown to be related to AD pathogenesis ([@B7]; [@B1]; [@B69]).

No certain evidence of gut microbiota alteration exists in AD patients yet. Nevertheless, gut microbiota alteration has been found in patients with multiple sclerosis and Parkinson's disease, in which neuroinflammation and protein misfolding were observed. Moreover, [@B9] reported that removing gut microbiota in the animal models of multiple sclerosis could hold back the progression of repalsing-remitting demyelination ([@B9]), and other studies described that oral ingestion of probiotics could relieve neuroinflammation ([@B61]; [@B108]).

[@B17] investigated the relationship between gut microbiota alteration and brain amyloidosis. Participants in this study were divided into three groups: cognitively impaired patients with amyloidosis (Amy+ group), cognitively impaired patients without amyloidosis (Amy- group) and cognitively healthy patients without amyloidosis (control group); the stool bacteria abundance and blood inflammation biomarkers were measured and compared among those three groups. The results showed that the Amy+ group had a unique bacteria alteration pattern, which was a smaller amount of *E. rectale* and larger amount of *Escherichia/Shigella* in stool compared with the other two groups, and furthermore, compared to the control group, the Amy+ group had a lower abundance of *Bacteroides fragilis.* The Amy+ group also showed higher serum concentrations of four cytokines (NLRP3, CXCL2, IL-6, and IL-1β) compared to the Amy- group and the control group. This study demonstrated the correlation among cytokines IL-1β, NLRP3 blood concentration and *Escherichia/Shigella* in the Amy+ and Amy- group, and the absence of correlation between IL-1β and CXCL2 with *E. rectale* in the Amy+ and Amy- groups; thus, the study concluded that the increase in pro-inflammatory gut bacteria, e.g., *Escherichia/Shigella*, and the decrease in anti-inflammatory gastrointestinal bacteria, e.g., *E. rectale*, might be one part of Alzheimer's disease pathology ([@B17]).

Moreover, endotoxin, as a bacterial product, has been discovered within senile plaques of Alzheimer's disease brain tissue ([@B41]). It has also been reported that the bacteria endotoxin is correlated with Alzheimer's disease pathological processes and amyloidosis. One study investigated the possible causes of Aβ plaque formation and reported that *E. coli* endotoxin could potentiate Aβ fibril formation *in vitro*, which could be part of AD pathogenesis ([@B4]).

It has been shown that the presence of an undefined number of LPSs (lipopolysaccharides) and amyloid plaques in the human gastrointestinal tract might participate in neuronal pathogenesis characterized by amyloidogenic features, such as AD ([@B39]; [@B62]; [@B109]; [@B44]; [@B93]). However, this hypothesis has not been tested.

During aging, the gut epithelium and blood-brain barrier tend to have higher permeability to small molecules. Therefore, LPSs, amyloids and other complexes excreted by fungi and bacteria in the gut more easily get through ([@B62]; [@B109]; [@B44]; [@B93]); thus, amyloid formation and dissemination caused by gut microbiota might be more influential in the elderly. Other studies have shown that the receptor for advanced glycosylation products (RAGE) and apolipoprotein E and J control the amyloid influx through the blood--brain barrier ([@B123]; [@B85]), while low density lipoprotein receptor-related protein monitors amyloid clearance ([@B25]), which could change in AD patients ([@B118]).

To date, these research studies show evidence that gut microbiota alteration may participate in Aβ plaque formation.

The correlation between constipation and Alzheimer's disease has been rarely mentioned before. However, there are some links between them. First, AD and constipation share a common risk factor, which is the high-fat-low-fiber diet pattern. Second, according to epidemiological data, the locations with high prevalence of Alzheimer's disease also have relatively high constipation prevalence. Third, constipation is associated with gut microbiota alteration, which may contribute to the occurrence of Aβ plaque formation.

Therefore, after evaluating evidence of the link between AD and constipation, we proposed the hypothesis that constipation may contribute to the occurrence of AD, and improving constipation for patients before the onset of AD may interfere with AD progression.

Summary and Perspectives
========================

The prevalence/incidence data analysis showed that Asian region have lower constipation prevalence and lower Dementia prevalence compared to other regions, which indicate Alzheimer's disease and constipation may be related or share a common factor. Moreover, the statistical positive correlation between AD and constipation lead us to think that constipation influenced Alzheimer's disease as with it affected colorectal cancer.

Furthermore, evidence shows the possible association between constipation and Alzheimer's disease. The gut-brain axis is a bidirectional path, and the gut microbiota play an important part in it. Through this bidirectional pathway, input from the gastrointestinal system to the CNS can contribute several symptoms, and the brain can affect gut microbiota function and composition. Gut microbiota participate in maintaining a normal gastrointestinal environment and have been shown to affect gastrointestinal motility. In return, a change in gut motility can also lead to gut microbiota alteration, and constipation has been thus demonstrated to be relevant to gastrointestinal bacteria alteration. Studies have demonstrated that the gut microbiota impact the neuronal system and the direct or indirect correlation between gut microbiota alteration and amyloidosis. For instance, the *E. coli* endotoxin has been shown to contribute to the formation of Aβ fibrils *in vitro*, and amyloids and LPSs have been found in the gastrointestinal tract, which might participate in brain amyloidosis. Furthermore, the blood-brain barrier and gastrointestinal epithelium tend to have higher permeability in the elderly, thus the consequences of gut microbiota alteration and toxic products of gastrointestinal bacteria may affect the brain more. Therefore, we propose the hypothesis that constipation may be related to Alzheimer's disease pathological processes.

As modern medicine faces a lack of effective Alzheimer's disease treatment, therapeutic approaches that could aid in preventing and/or delaying the onset of AD are required; thus, we present the idea that ameliorating constipation in patients before the onset of Alzheimer's disease may prevent or delay Alzheimer' disease progression.

Study Limitation
================

This study has some limitations. First, criteria and time of data collection across studies were different, which might cause some inaccuracy in our research; however, there are several studies that show that AD prevalence is lower in developing countries or lower income areas ([@B42]; [@B20]; [@B79]; [@B31]); thus, AD incidence worldwide probably fits our assumption.

Second, population aging trends in developed countries might influence the AD epidemiology results. AD prevalence increases exponentially with age; for instance, among those who are 65--74 years old, the incidence is 3% and increases dramatically to 50% among those 85 years or older ([@B16]); therefore, the age distribution differences between developed and developing countries might be an influential factor.

Third, some researchers speculate that milder dementia or AD have not been detected due to lack of awareness; older people are highly supported in some countries and reluctant to report their possible mental defects, which all contribute to difficulties in obtaining accurate numbers.

Fourth, epidemiological database is not fully accessible, therefore the prevalence data used to do correlation analysis is incomprehensive, which may bias the accuracy of the correlation statistical analysis. To further demonstrate the correlation between Constipation and Alzheimer's disease, more extensive data retrieval and analysis were needed.
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